Introduction:

The emergence of the liver damage is frequent in the clinical course of the infection due to the dengue virus, which is associated to the oxidative stress.

Objective:

To demonstrate the effectiveness of the Vimang® concentrate in patients with diagnosis of liver damage due to dengue virus.

Methods:

A clinical open and randomized assay in phase III was carried out, in the Hepathology department of "Saturnino Lora Torres" Teaching Provincial Clinical Surgical Hospital in Santiago de Cuba, from June, 2014 to the same month in 2017, consistent in the use of Vimang® concentrate in 39 patients with reactive hepatitis due to dengue fever, who formed the study group, and then the results were compared with those of the control group, integrated by equally number of patients with the affection, in whom the habitual hygienic-dietary measures were applied.

Results:

In the series an important decrease of the mean values of the tests was obtained to evaluate the hepatic function in both groups, but they were more significant in the patients who received Vimang®. In the same way, an improvement was appreciated after 9 months in 89.0 % of the cases as for the decrease of the symptoms, compared to a 69.2 % of the controls. Hepatomegaly, as the most important physical sign, disappeared in the total of the cases after a year of clinical follow-up; however, it remained in 7.2 % of the control group.

Conclusions:

It could be demonstrated that Vimang® influences in a significant way in the control of the symptoms and in the humoral improvement of the patients who present liver damage caused by dengue fever.

        · resumen en Español     · texto en Español     · Español ( pdf )